Table 3 Sex differences in SIRs of malignancy in patients with SLE compared to general populations

Overall malignancies

1.75 (1.63, 1.87)

1.72 (1.60, 1.84)

2.05 (1.65, 2.46)

Solid malignancy

1.65 (1.53, 1.77)

1.64 (1.51, 1.76)

1.78 (1.39, 2.16)

 Breast and reproductive system

1.45 (1.23, 1.66)

1.43 (1.21, 1.65)

1.76 (0.72, 2.81)

 Thyroid

1.58 (1.33, 1.82)

1.55 (1.30, 1.80)

2.56 (0.51, 4.61)

 Liver

1.86 (1.40, 2.32)

1.98 (1.46, 2.50)

1.32 (0.40, 2.23)

 Colon

1.73 (1.30, 2.16)

1.69 (1.23, 2.16)

1.91 (0.73, 3.10)

 Lung

1.80 (1.20, 2.41)

1.73 (1.05, 2.41)

2.03 (0.70, 3.35)

 Pancreas

1.96 (1.28, 2.63)

2.00 (1.27, 2.72)

1.64 (0, 3.50)

 Stomach

1.09 (0.71, 1.48)

1.17 (0.73, 1.60)

0.76 (0.02, 1.51)

 Bladder

2.44 (1.06, 3.83)

2.74 (1.04, 4.44)

1.58 (0, 3.77)

 Head and neck

2.65 (1.08, 4.21)

2.71 (0.94, 4.47)

2.41 (0, 5.75)

 Kidney

1.78 (0.68, 2.89)

1.06 (0.13, 1.99)

5.54 (0.68, 10.39)

 Biliary tract

1.03 (0.27, 1.80)

0.69 (0.01, 1.37)

3.00 (0, 6.39)

 Brain and central nervous system

0.91 (0.11, 1.72)

1.01 (0.12, 1.89)

NC

 Larynx

2.59 (1.00, 6.17)

5.02 (0, 11.98)

NC

Haematology malignancy

5.87 (4.48, 7.27)

5.22 (3.80, 6.64)

9.89 (5.05, 14.74)

 Non-Hodgkin lymphoma

6.24 (4.20, 8.27)

5.33 (3.32, 7.34)

12.71 (4.41, 21.02)

 Multiple myeloma

8.19 (3.90, 12.48)

8.95 (4.08, 13.82)

3.90 (0, 11.53)

 Leukaemia

3.64 (1.58, 5.70)

2.87 (0.88, 4.86)

7.80 (0.16, 15.45)

 Hodgkin lymphoma

7.53 (1.00, 16.05)

9.41 (0, 20.06)

NC